722 주식 개요 바이오 제약 회사인 Antengene Corporation Limited는 중화권 및 국제적으로 새로운 종양 치료법을 개발하는 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Antengene Corporation Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Antengene 과거 주가 현재 주가 HK$0.073 52주 최고치 HK$0.15 52주 최저치 HK$0.025 베타 0.72 1개월 변경 18.55% 3개월 변경 사항 1.38% 1년 변경 사항 -50.67% 3년 변화 -88.78% 5년 변화 n/a IPO 이후 변화 -95.87%
최근 뉴스 및 업데이트
Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025 Jan 22
Antengene Corporation Limited Announces Xpovio's New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to Dlbcl Patients in the Country Nov 28
South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO Oct 18
First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023) Sep 30
Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications Sep 23
First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023) Aug 27 더 많은 업데이트 보기
Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025 Jan 22
Antengene Corporation Limited Announces Xpovio's New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to Dlbcl Patients in the Country Nov 28
South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO Oct 18
First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023) Sep 30
Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications Sep 23
First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023) Aug 27
Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024 Aug 01
Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024 Jul 31
Antengene Corporation Limited Announces China National Medical Products Administration Approves New Indication in DLBCL in China, Bringing A New Treatment Option to Patients in the Country Jul 06
Full year 2023 earnings released: CN¥0.94 loss per share (vs CN¥0.97 loss in FY 2022) Mar 24
Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024 Mar 23
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study Mar 20
Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024 Mar 12
New minor risk - Market cap size Mar 04
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Dec 14
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States Dec 11
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Dec 06
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day Nov 17
Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031 Sep 22
New minor risk - Shareholder dilution Sep 20
First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022) Aug 27
Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 16
Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Jul 17
Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Jun 03
Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers May 24
Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 May 18
Less than half of directors are independent Mar 27
Antengene Corporation Limited Announces Executive Changes Dec 07
Less than half of directors are independent Nov 16
Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer Nov 16
Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting Nov 08
Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037 Nov 03
Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors Nov 01
Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma Oct 22
First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021) Sep 02
Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma Aug 03 Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022
Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors Jun 08
Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018 Jun 07
Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors May 31
Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas May 23
Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China May 19
Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China May 18
Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China May 16
Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress May 14
Less than half of directors are independent Apr 27
Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018 Apr 27
Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine Apr 07
Antengene Corporation Limited Announces Management Changes Mar 31
Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes Mar 30 Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037 Feb 07
Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors Dec 30
Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial Dec 20
National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China Dec 18
Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting Dec 15
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors Dec 13
Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China Aug 24
Antengene Announces The Approval by Human Research Ethics Committeein Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma Jul 23
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF) Jul 07 주주 수익률 722 DE Pharmaceuticals DE 마켓 7D 8.9% 1.2% 1.5% 1Y -50.7% -13.4% 12.6%
전체 주주 수익률 보기
수익률 대 산업: 722 지난 1년 동안 -13.4 %를 반환한 German Pharmaceuticals 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 722 지난 1년 동안 12.6 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 722's price volatile compared to industry and market? 722 volatility 722 Average Weekly Movement 22.9% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.3%
안정적인 주가: 722 의 주가는 지난 3개월 동안 German 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: 722 의 주간 변동성 ( 23% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 바이오 제약 회사인 안텐진 코퍼레이션은 중화권 및 국제적으로 새로운 종양 치료법을 개발하는 기업입니다. 회사의 상용화된 자산에는 중국 본토, 싱가포르, 호주, 홍콩, 마카오, 대만 성인 환자의 재발성/불응성 다발성 골수종(rrMM), 재발성/불응성 미만성 거대 B세포 림프종, 다발성 골수종(MM) 등 다양한 혈액암 및 고형 종양 치료를 위한 경구용 SINE 화합물인 ATG-010(셀린엑스소르)이 있습니다. 후기 단계 제품 후보로는 자궁경부암 및 기타 진행성 고형 종양 치료를 위한 mTOR 키나제 억제제인 ATG-008(오나타서팁)이 있습니다.
자세히 보기 Antengene Corporation Limited 기본 사항 요약 Antengene 의 수익과 매출은 시가총액과 어떻게 비교하나요? 722 기본 통계 시가총액 €63.19m 수익(TTM ) -€69.66m 수익(TTM ) €7.38m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 722 손익 계산서(TTM ) 수익 CN¥56.07m 수익 비용 CN¥8.50m 총 이익 CN¥47.57m 기타 비용 CN¥577.09m 수익 -CN¥529.52m
주당 순이익(EPS) -0.78 총 마진 84.84% 순이익 마진 -944.43% 부채/자본 비율 18.1%
722 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/27 13:51 장 마감 주가 2025/01/24 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Antengene Corporation Limited 7 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Ziyu He China International Capital Corporation Limited Wangbin Zhou Citigroup Inc Ruili Bian Citigroup Inc
4 더 많은 분석가 보기 